Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00035024.xml
Download PDF
Thromb Haemost 1999; 82(02): 486-493
DOI: 10.1055/s-0037-1615869
DOI: 10.1055/s-0037-1615869
Research Article
Safety of Blood Products: Are Transmissible Spongiform Encephalopathies (Prion Diseases) a Risk?
Further Information
Publication History
Publication Date:
09 December 2017 (online)
-
References
- 1 Prusiner S. Prions. Proc Natl Acad Sci. USA 1998; 95: 13363-13383.
- 2 Pan K-M, Baldwin M, Nguyen J, Gasset M, Serban A, Groth D, Mehlhorn I, Huang Z, Fletterick RJ, Cohen FE, Prusiner SB. Conversion of a-helices into b-sheets features in the formation of the scrapie prion proteins. Proc Natl Acad Sci USA 1993; 90: 10962-10966.
- 3 Telling GC, Scott M, Mastrianni J, Gabizon R, Torchia M, Cohen FE, DeArmond SJ, Prusiner SB. Prion propagation in mice expressing human and chimeric PrP transgenes implicates the interaction of cellular PrP with another protein. Cell 1995; 83: 79-90.
- 4 Brown P. Transmissible human spongiform encephalopathy (infectious cerebral amyloidosesis): Creutzfeldt-Jakob Disease, Gerstmann-Sträussler-Scheinker Syndrome and Kuru. In: Calne DB. ed. Neurodegenerative Diseases. Philadelphia: WB Saunders; 1994: 839-876.
- 5 Gajdusek DC. Infectious amyloids: Subacute spongiform encephalopathies as transmissible cerebral amyloidoses. In: Knipe BN, Howley PM. eds. Fields Virology. 3rd ed.. Philadelphia: Lippincott-Raven; 1996: 2862-2870.
- 6 Brown P, Preece M, Will R. “Friendly fire” in medicine: hormones, homografts, and Creutzfeldt-Jakob disease. Lancet 1992; 340: 24-27.
- 7 Brown P. Transmission of spongiform encephalopathy through biological products. Safety of biological products prepared from mammalian cell culture. In: Brown F, Griffiths E, Horaud F, Petricciani JC. eds. Dev Biol Stand. Basel: Karger; 1998. 93 73-78.
- 8 Will RG, Ironside JM, Zeidler M, Cousens SN, Estibeiro K, Alperovich A, Poser S, Pocchiari M, Hofman A. A new variant of Creutzfeldt-Jakob Disease in the UK. Lancet 1996; 347: 921-925.
- 9 Bruce ME, Will RG, Ironside JW, McConnell I, Drummond D, Suttle A, McCardle L, Chree A, Hope J, Birkett C, Cousens S, Fraser H, Bostock CJ. Transmissions to mice indicate that “new variant” CJD is caused by the BSE agent. Nature 1997; 389: 498-501.
- 10 Collinge J, Sidle KCL, Meads J, Ironside J, Hill AF. Molecular analysis of prion strain variation and the aetiology of “new variant’ CJD. Nature 1996; 383: 685-690.
- 11 Hill AF, Desbruslais M, Joiner S, Sidle KCL, Gowland I, Collinge J, Doey LJ, Lantos P. The same prion strain causes nvCJD and BSE. Nature 1997; 389: 448-450
- 12 Brown P, Gibbs CJ, Rodgers-Johnson P, Asher DM, Sulima MP, Bacote A, Goldfarb LG, Gajdusek DC. Human spongiform encephalopathy: The National Institutes of Health Series of 300 Cases of Experimentally Transmitted Disease. Ann Neurol 1994; 35: 513-529.
- 13 Tateishi J, Brown P, Kitamoto T, Hoque ZM, Roos R, Wollman R, Cervenakova L, Gajdusek DC. First experimental transmission of fatal familial insomnia. Nature 1995; 376: 434 435.
- 14 Dealler S. A matter for debate: the risk of bovine spongiform encephalopathy to humans posed by blood transfusion in the UK. Transfus Med 1996; 6: 217-222.
- 15 Will RG, Cousens SN, Farrington CP, Smith PG, Knight RSG, Ironside JW. Death from variant Creutzfeldt-Jakob disease. Lancet 1999; 353: 979.
- 16 Hill AF, Zeidler M, Ironside JW, Collinge J. Diagnosis of new variant Creutzfeldt-Jakob disease by tonsil biopsy. Lancet 1997; 349: 99-100.
- 17 Hill AF, Butterworth RJ, Joiner S, Jackson G, Rossor MN, Thomas DJ, Frosh A, Tolley N, Bell JE, Spencer M, King A, Al-Sarraj S, Ironside JW, Lantos PL, Collinge J. Investigation of variant Creutzfeldt-Jakob disease and other human prion diseases with tonsil biopsy samples. Lancet 1997; 353: 183-189.
- 18 Hilton DA, Fathers E, Edwards P, Ironside JW, Zajicek J. Prion immunoreactivity in appendix before clinical onset of variant Creutzfeldt-Jakob disease. Lancet 1998; 352: 703 704.
- 19 Barbara J, Flanagan P. Blood transfusion risk: protecting against the unknown (editorial). Br Med J 1998; 316: 717-718.
- 20 Warden J. Blood supplies to be treated to reduce CJD risk. Br Med J 1998; 317: 232.
- 21 Ziedler M, Johnstone EC, Bamber RWK, Dickens CM, Fisher CJ, Francis AF, Goldbeck R, Higgo R, Johnson-Sabine EC, Lodge GJ, McGarry P, Mitchell S, Tarlo L, Turner M, Ryley P, Will RG. New variant Creutzfeldt-Jakob disease: psychiatric features. Lancet 1997; 350: 908-910.
- 22 Kawashima I, Furukawa H, Doh-ura K, Iwaki T. Diagnosis of new variant Creutzfeldt-Jakob disease by tonsil biopsy. Lancet 1997; 350: 68-69.
- 23 Davanipour Z, Alter M, Sobel E, Asher DM, Gajdusek DC. Creutzfeldt-Jakob disease: possible medical risk factors. Neurology 1985; 35: 1483-1486.
- 24 Harries-Jones R, Knight R, Will RG, Cousens S, Smith PG, Matthews WB. Creutzfeldt-Jakob disease in England and Wales, 1980-1984: a case control study of potential risk factors. J Neurol Neurosurg Psychiatry 1988; 51: 1113-1119.
- 25 Esmonde TFG, Will RG, Slattery JM, Knight R, Harries-Johnes R, de Silva R, Matthews WB. Creutzfeldt-Jakob disease and blood transfusion. Lancet 1993; 341: 205-207.
- 26 Wientjens DPWM, Davanipour Z, Hofman A, Kondo K, Matthews WB, Will RG, van Duijn CM. Risk factors for Creutzfeldt-Jakob disease: a reanalysis of case-control studies. Neurology 1996; 46: 1287-1291.
- 27 Van Duijn CM, Delasnerie-Lauprêtre N, Masullo C, Zerr I, de Silva R, Wientjens DPWM, Brandel J-P, Weber T, Bonavita V, Zeidler M, Alpérovitch A, Poser S, Granieri E, Hofman A, Will RG. Case-Control study of risk factors of Creutzfeldt-Jakob disease in Europe during 1993-95. Lancet 1998; 351: 1081-85.
- 28 Kondo K, Kuroiwa Y. A case control study of Creutzfeldt-Jakob disease: association with physical injuries. Ann Neurol 1982; 11: 377-381.
- 29 Sullivan MT, Schonberger LB, Kessler D, Williams AE, Dodd RY. Creutzfeldt-Jakob disease (CJD) investigational look back study. Transfusion 1997; 37 (Suppl): 2S.
- 30 Cashman NR, Loertscher R, Nalbantoglu J, Shaw I, Kascsak RJ, Bolton DC, Bendheim PE. Cellular isoform of the scrapie agent protein participates in lymphocytes activation. Cell 1990; 61: 185-192
- 31 Bendheim PE, Brown HR, Rudelli RD, Scala LJ, Goller NL, Wen GY, Kascsak RJ, Cashman NR, Bolton DC. Nearly ubiquitous tissue distribution of the scrapie agent precursor protein. Neurology 1992; 42: 149-156
- 32 Perrini F, Vidal R, Ghetti B, Tagliavini F, Frangione B, Preli F. PRP 27-30 is a normal soluble prion protein fragment released by human platelets. Biochem Biophys Res Commun 1996; 223: 572-577.
- 33 Dodelet VC, Cashman NR. Prion protein expression in human leukocyte differentiation. Blood 1998; 91: 1556-1561.
- 34 Holada K, Mondoro TH, Muller J, Vostal JG. Increased expression of phosphatidylinositol-specific phospholipase C resistant prion proteins on the surface of activated platelets. Br J Hematol 1998; 103: 276-282.
- 35 Heye N, Hensen S, Müller N. Creutzfeldt-Jakob Disease and blood transfusion. Lancet 1994; 343: 298-299.
- 36 Evatt B, Austin H, Barnhart E, Schonberger L, Sharer L, Jones R, DeArmond S. Surveillance for Creutzfeldt-Jakob disease among persons with hemophilia. Transfusion 1998; 38: 817-820.
- 37 Holman RC, Khan AS, Belay ED, Schonberger LB. Creutzfeldt-Jakob disease in the United States, 1979-1994: using national mortality data to assess the possible occurrence of variant cases. Emerg Infect Dis 1996; 2: 333-337.
- 38 Lee CA, Ironside JW, Bell JE, Giangrande P, Ludlam C, Esiri MM, McLaughin JE. Retrospective neuropathological review of prion disease in UK haemophilic patients. Thromb Haemost 1998; 80: 909-911.
- 39 Klein R, Dumble LJ. Transmission of Creutzfeldt-Jakob disease and blood transfusion. Lancet 1993; 341: 768.
- 40 Creange A, Gray F, Cesaro P, Degos J-D. Pooled plasma derivatives and Creutzfeldt-Jakob disease. Lancet 1996; 347: 482.
- 41 Ricketts M, Cashman NR, Stratton EE, ElSaadany S. Is Creutzfeldt-Jakob Disease Transmitted in Blood?. Emerg Infect Dis 1997; 3: 155-163.
- 42 Tateishi J. Transmission of Creutzfeldt-Jakob disease from human blood and urine into mice. Lancet 1985; ii: 1074
- 43 Manuelidis EE, Kim JH, Mericangas JR, Manuelidis L. Transmission to animals of Creutzfeldt-Jakob disease from human blood. Lancet 1985; ii: 896-897.
- 44 Deslys JP, Lasmezas C, Dormont D. Selection of specific strains in iatrogenic Creutzfeldt-Jakob disease. Lancet 1994; 343: 848-849.
- 45 Tamai Y, Kojuma H, Kitajima R, Taguchi F, Ohtani Y, Kwaguchi T, Miura S, Sato M. Demonstration of the transmissible agent in tissue from pregnant woman with Creutzfeldt-Jakob disease. N Engl J Med 1992; 327: 649.
- 46 Hadlow WJ, Kennedy RC, Race RE, Eklund CM. Virologic and neurohistologic findings in dairy goats affected with natural scrapie. Vet Pathol 1980; 17: 187-199.
- 47 Hadlow WJ, Kennedy RC, Race RE. Natural infection of Suffolk sheep with scrapie virus. J Infect Dis 1982; 146: 657-664.
- 48 Pattison J. The emergence of bovine spongiform encephalopathy and related diseases. Emerg Infect Dis 1998; 4: 390-394.
- 49 Gibbs Jr CJ, Gajdusek DC, Morris JA. Viral characteristics of the scrapie agent in mice. In: Gajdusek DC, Gibbs Jr CJ, Alpers M. eds Slow, Latent, and Temperate Virus Infections. NINDB monograph no. 2, PHS Publication No. 1378 Washington DC: US Government Printing Office; 1965: 195-202.
- 50 Clarke MC, Haig DA. Presence of the transmissible agent of scrapie in the serum of affected mice and rats. Vet Rec 1967; 80: 504.
- 51 Dickinson AG, Miekle VMH. Genetic control of the concentration of ME7 scrapie agent in the brain of mice. J Comp Pathol 1969; 79: 15-22.
- 52 Diringer H. Sustained viremia in experimental hamster scrapie. Arch Virol 1984; 82: 105-109.
- 53 Casaccia P, Ladogana A, Xi YG, Pocchiari M. Levels of infectivity in the blood throughout the incubation period of hamsters peripherally injected with scrapie. Arch Virol 1989; 108: 145-149.
- 54 Manuelidis EE, Gorgacz EJ, Manuelidis L. Viremia in experimental Creutzfeldt-Jakob disease. Science 1978; 200: 1069-1071.
- 55 Kuroda Y, Gibbs Jr. CJ, Amyz HL, Gajdusek DC. Creutzfeldt-Jakob disease in mice: persistent viremia and preferential replication of virus in low-density lymphocytes. Infect Immun 1983; 41: 154-161.
- 56 Brown P, Rohwer RG, Dunstan BC, MacAuley C, Gajdusek DC, Drohan WN. The distribution of infectivity in blood components and plasma derivatives in experimental models of transmissible spongiform encephalopathy. Transfusion 1998; 38: 810-816.
- 57 Brown P. Can Creutzfeldt-Jakob disease be transmitted by transfusion?. Curr Opin Hematol 1995; 2: 472-477.
- 58 Brown P. The risk of blood-borne Creutzfeldt-Jakob disease. In: Court L, Dodet B. eds. Transmissible Subacute Spongiform Encephalopathies: Prion Diseases. Paris: Elsevier; 1996: 447-450.
- 59 Brown P. Donor pool size and the risk of blood-borne Creutzfeldt-Jakob disease. Transfusion 1998; 38: 312-315.
- 60 Dodd RY, Sullivan MT. Creutzfeldt-Jakob disease and transfusion safety: tilting at icebergs?. Transfusion 1998; 38: 221-223.
- 61 Larke B. The quandary of Creutzfeldt-Jakob disease. CMAJ 1998; 159: 789-792.